A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis
Summary A double-blind crossover trial using the double-dummy technique was carried out in 30 patients with osteoarthritis. The original design was to compare the efficacy and tolerability of l 'Osmosin', the new osmotic-release formulation delivering 7 mg indomethacin per hour for approxi...
Gespeichert in:
| Veröffentlicht in: | Current medical research and opinion 1983, Vol.8 (S2), p.90-98 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 98 |
|---|---|
| container_issue | S2 |
| container_start_page | 90 |
| container_title | Current medical research and opinion |
| container_volume | 8 |
| creator | Williams, P. Currie, W.J. C. VandenBurg, M. J. |
| description | Summary
A double-blind crossover trial using the double-dummy technique was carried out in 30 patients with osteoarthritis. The original design was to compare the efficacy and tolerability of l 'Osmosin', the new osmotic-release formulation delivering 7 mg indomethacin per hour for approximately 10 hours, with that of benoxaprofen (600 mg). Each treatment was to have been given as a single daily dose, at night, for 4 weeks, before crossing over to the alternative medication. Because of the withdrawal of benoxaprofen from the U.K. market just as 14 patients had completed their first treatment period, the study was continued as an 'Osmosin' versus placebo trial after crossover. Comparison of the results of first treatments showed that 'Osmosin' was significantly better than placebo and at least as effective as benoxaprofen in reducing pain scores, particularly day and weight-bearing pain. The crossover data supported these findings. 'Osmosin' proved to be well tolerated, with a side-effect profile similar to that of placebo. |
| doi_str_mv | 10.1185/03007998309109828 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_informahealthcare_journals_10_1185_03007998309109828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80481126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-72666ee75931725feeac5f519f1745aaed4784ea8daf4081dca051309b8967cf3</originalsourceid><addsrcrecordid>eNp9kEFrFTEUhYNY6rP6A1wIWdmNY5OZzCTBbkqxKhS6adfhTuaGl5JJnkmG2n_vPN5DEKGruzjnO5x7CPnA2RfOVX_BOsak1qpjmjOtWvWKbLiQXSOUlK_JZq83q6F_Q96W8sgYb5XWp-R06ESrh2FD7BWd0jIGbMbg40RtmneQfUmRJkfP78qcio_nn-mIMf2GXU4OI4XVuQtgcUzUR1q3SGtGqDPGuudSqZgg12321Zd35MRBKPj-eM_Iw823--sfze3d95_XV7eNFYzXRrbDMCDKXndctr1DBNu7nmvHpegBcBJSCQQ1gRNM8ckC6_n6-qj0IK3rzsinQ-7a8teCpZrZF4shQMS0FKOYUJy3w2rkB6PNqZSMzuyynyE_G87Mfljz37Ar8_EYvowzTn-J45KrfnnQfXQpz_CUcphMheeQsssQrS-meyn-6z_4FiHUrYWM5jEtOa67vVDuDxc7mUU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80481126</pqid></control><display><type>article</type><title>A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Williams, P. ; Currie, W.J. C. ; VandenBurg, M. J.</creator><creatorcontrib>Williams, P. ; Currie, W.J. C. ; VandenBurg, M. J.</creatorcontrib><description>Summary
A double-blind crossover trial using the double-dummy technique was carried out in 30 patients with osteoarthritis. The original design was to compare the efficacy and tolerability of l 'Osmosin', the new osmotic-release formulation delivering 7 mg indomethacin per hour for approximately 10 hours, with that of benoxaprofen (600 mg). Each treatment was to have been given as a single daily dose, at night, for 4 weeks, before crossing over to the alternative medication. Because of the withdrawal of benoxaprofen from the U.K. market just as 14 patients had completed their first treatment period, the study was continued as an 'Osmosin' versus placebo trial after crossover. Comparison of the results of first treatments showed that 'Osmosin' was significantly better than placebo and at least as effective as benoxaprofen in reducing pain scores, particularly day and weight-bearing pain. The crossover data supported these findings. 'Osmosin' proved to be well tolerated, with a side-effect profile similar to that of placebo.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/03007998309109828</identifier><identifier>PMID: 6342966</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; benoxaprofen ; Clinical Trials as Topic ; Delayed-Action Preparations ; dosage forms ; Double-Blind Method ; Drug Tolerance ; Female ; Humans ; Indomethacin ; Indomethacin - administration & dosage ; Male ; Middle Aged ; Osmosin ; Osmosis ; osteoarthritis ; Osteoarthritis - drug therapy ; Propionates - therapeutic use</subject><ispartof>Current medical research and opinion, 1983, Vol.8 (S2), p.90-98</ispartof><rights>1983 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1983</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-72666ee75931725feeac5f519f1745aaed4784ea8daf4081dca051309b8967cf3</citedby><cites>FETCH-LOGICAL-c401t-72666ee75931725feeac5f519f1745aaed4784ea8daf4081dca051309b8967cf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1185/03007998309109828$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1185/03007998309109828$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6342966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Williams, P.</creatorcontrib><creatorcontrib>Currie, W.J. C.</creatorcontrib><creatorcontrib>VandenBurg, M. J.</creatorcontrib><title>A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>Summary
A double-blind crossover trial using the double-dummy technique was carried out in 30 patients with osteoarthritis. The original design was to compare the efficacy and tolerability of l 'Osmosin', the new osmotic-release formulation delivering 7 mg indomethacin per hour for approximately 10 hours, with that of benoxaprofen (600 mg). Each treatment was to have been given as a single daily dose, at night, for 4 weeks, before crossing over to the alternative medication. Because of the withdrawal of benoxaprofen from the U.K. market just as 14 patients had completed their first treatment period, the study was continued as an 'Osmosin' versus placebo trial after crossover. Comparison of the results of first treatments showed that 'Osmosin' was significantly better than placebo and at least as effective as benoxaprofen in reducing pain scores, particularly day and weight-bearing pain. The crossover data supported these findings. 'Osmosin' proved to be well tolerated, with a side-effect profile similar to that of placebo.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>benoxaprofen</subject><subject>Clinical Trials as Topic</subject><subject>Delayed-Action Preparations</subject><subject>dosage forms</subject><subject>Double-Blind Method</subject><subject>Drug Tolerance</subject><subject>Female</subject><subject>Humans</subject><subject>Indomethacin</subject><subject>Indomethacin - administration & dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Osmosin</subject><subject>Osmosis</subject><subject>osteoarthritis</subject><subject>Osteoarthritis - drug therapy</subject><subject>Propionates - therapeutic use</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFrFTEUhYNY6rP6A1wIWdmNY5OZzCTBbkqxKhS6adfhTuaGl5JJnkmG2n_vPN5DEKGruzjnO5x7CPnA2RfOVX_BOsak1qpjmjOtWvWKbLiQXSOUlK_JZq83q6F_Q96W8sgYb5XWp-R06ESrh2FD7BWd0jIGbMbg40RtmneQfUmRJkfP78qcio_nn-mIMf2GXU4OI4XVuQtgcUzUR1q3SGtGqDPGuudSqZgg12321Zd35MRBKPj-eM_Iw823--sfze3d95_XV7eNFYzXRrbDMCDKXndctr1DBNu7nmvHpegBcBJSCQQ1gRNM8ckC6_n6-qj0IK3rzsinQ-7a8teCpZrZF4shQMS0FKOYUJy3w2rkB6PNqZSMzuyynyE_G87Mfljz37Ar8_EYvowzTn-J45KrfnnQfXQpz_CUcphMheeQsssQrS-meyn-6z_4FiHUrYWM5jEtOa67vVDuDxc7mUU</recordid><startdate>1983</startdate><enddate>1983</enddate><creator>Williams, P.</creator><creator>Currie, W.J. C.</creator><creator>VandenBurg, M. J.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1983</creationdate><title>A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis</title><author>Williams, P. ; Currie, W.J. C. ; VandenBurg, M. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-72666ee75931725feeac5f519f1745aaed4784ea8daf4081dca051309b8967cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>benoxaprofen</topic><topic>Clinical Trials as Topic</topic><topic>Delayed-Action Preparations</topic><topic>dosage forms</topic><topic>Double-Blind Method</topic><topic>Drug Tolerance</topic><topic>Female</topic><topic>Humans</topic><topic>Indomethacin</topic><topic>Indomethacin - administration & dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Osmosin</topic><topic>Osmosis</topic><topic>osteoarthritis</topic><topic>Osteoarthritis - drug therapy</topic><topic>Propionates - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Williams, P.</creatorcontrib><creatorcontrib>Currie, W.J. C.</creatorcontrib><creatorcontrib>VandenBurg, M. J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Williams, P.</au><au>Currie, W.J. C.</au><au>VandenBurg, M. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>1983</date><risdate>1983</risdate><volume>8</volume><issue>S2</issue><spage>90</spage><epage>98</epage><pages>90-98</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><abstract>Summary
A double-blind crossover trial using the double-dummy technique was carried out in 30 patients with osteoarthritis. The original design was to compare the efficacy and tolerability of l 'Osmosin', the new osmotic-release formulation delivering 7 mg indomethacin per hour for approximately 10 hours, with that of benoxaprofen (600 mg). Each treatment was to have been given as a single daily dose, at night, for 4 weeks, before crossing over to the alternative medication. Because of the withdrawal of benoxaprofen from the U.K. market just as 14 patients had completed their first treatment period, the study was continued as an 'Osmosin' versus placebo trial after crossover. Comparison of the results of first treatments showed that 'Osmosin' was significantly better than placebo and at least as effective as benoxaprofen in reducing pain scores, particularly day and weight-bearing pain. The crossover data supported these findings. 'Osmosin' proved to be well tolerated, with a side-effect profile similar to that of placebo.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>6342966</pmid><doi>10.1185/03007998309109828</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-7995 |
| ispartof | Current medical research and opinion, 1983, Vol.8 (S2), p.90-98 |
| issn | 0300-7995 1473-4877 |
| language | eng |
| recordid | cdi_informahealthcare_journals_10_1185_03007998309109828 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Adolescent Adult Aged Anti-Inflammatory Agents, Non-Steroidal - therapeutic use benoxaprofen Clinical Trials as Topic Delayed-Action Preparations dosage forms Double-Blind Method Drug Tolerance Female Humans Indomethacin Indomethacin - administration & dosage Male Middle Aged Osmosin Osmosis osteoarthritis Osteoarthritis - drug therapy Propionates - therapeutic use |
| title | A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T18%3A42%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20double-blind%20comparison%20of%20'Osmosin',%20benoxaprofen%20and%20placebo%20in%20the%20treatment%20of%20osteoarthritis&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Williams,%20P.&rft.date=1983&rft.volume=8&rft.issue=S2&rft.spage=90&rft.epage=98&rft.pages=90-98&rft.issn=0300-7995&rft.eissn=1473-4877&rft_id=info:doi/10.1185/03007998309109828&rft_dat=%3Cproquest_infor%3E80481126%3C/proquest_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80481126&rft_id=info:pmid/6342966&rfr_iscdi=true |